(P018) Low-Dose-Rate, Permanent Prostate Brachytherapy Is an Effective Treatment Option for Men Less Than 55 Years Old With Low-Risk Prostate Cancer
Prostate brachytherapy is an effective treatment for men younger than 55 years with low-risk prostate cancer. Prostate brachytherapy should be considered for all men diagnosed with low-risk prostate cancer, regardless of age.
Brian J. Moran, MD, Michelle H. Braccioforte, MS, MPH, Gregory C. Treharne, MD; Prostate Cancer Foundation of Chicago; Department of Radiation Medicine, University of Kentucky
PURPOSE/OBJECTIVE(S): To ascertain the effectiveness of low-dose-rate, interstitial, permanent prostate brachytherapy (PB) treatment in a large series of “young” patients with prostate cancer, treated at a single institution.
MATERIALS AND METHODS: A retrospective review was performed of all patients aged < 55 years treated with PB for low-risk prostate cancer between November 1997 and October 2012. Inclusion criteria were low-risk prostate cancer as defined by National Comprehensive Cancer Network guidelines of Gleason Score (GS) 6 or less, pretreatment prostate-specific antigen (PSA) < 10.0 ng/mL, and clinical stage ≤ T2a. A total of 332 patients meeting these criteria were identified; however, follow-up PSA data were available for 177 patients. Mean age was 51.3 years; mean follow-up was 4.89 years (range: 2 mo–15 yr). The mean pretreatment PSA was 5.66 ng/mL (range: 0.6–9.9 ng/mL). All patients underwent PB with 131Cs, 103Pd, or 125I. Four patients also received external beam radiotherapy (EBRT), and 12 patients received androgen deprivation therapy as part of their treatment. Progression-free survival (PFS) and overall survival (OS) were calculated from the time of PB, using Kaplan-Meier statistics.
RESULTS: In this cohort of patients, there were five PSA failures (as defined by the Phoenix definition) and four deaths (unrelated to prostate cancer). PFS was 96.2% at 5 years and 95.3% at 10 years; OS was 99.3% at 5 years and 89.4% at 10 years.
CONCLUSION: PB is an effective treatment for men aged < 55 years with low-risk prostate cancer. PB should be considered for all men diagnosed with low-risk prostate cancer, regardless of age.
Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
